Shuo Yang, Zhenfeng Zhang, Xi He, Zilu Ouyang, Shuzhen Tang, Manshan Liang, Zhuowen Chen, Yinghua Liu, Yang Huang, Yeneng Dai, ShengFeng HUANG, Bihui Cao, Zhe-Sheng Chen, Xian Yu, Qi Zhao
. A B7-H3-targeted bispecific killer cell engager (BiKE) was constructed, and antibody-dependent cell-mediated cytotoxicity (ADCC) was measured to evaluate its combined effect with luteolin. The B7-H3-targeted BiKE showed superior activity when combined with luteolin compared to either treatment of luteolin or BiKE alone. Our findings not only identify B7-H3 as a promising therapeutic target for NSCLC but also suggest luteolin as a potential anticancer adjuvant. The rationally designed combination strategy presented here may enhance existing treatment paradigms for NSCLC.